Abstract: The present invention relates to a rare element composition for preventing or suppressing a cancer or cancer relapse. The composition comprises selenium, molybdenum, zinc, germanium, magnesium, iron and iodine. Also provided is a method for preventing or suppressing a cancer or a cancer relapse, comprising administering the composition of the invention to a subject.

Abstract: Provided is a compound of Formula (I) below, or a pharmaceutically acceptable salt, metabolite, or prodrug thereof: wherein: A1 is CR4 or N; A2 is CR5R6 or NR7; A3 is CR5?R6? or NR7?; each of R1, R2, R2?, R3, R3?, R4, R5, R5?, R6, R6?, R7, and R7?, independently, is hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, amino, formyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkylamine, C3-20 carbocyclyl, or C3-20 heterocyclyl; or R5 and R6, R5? and R6?, or R5 and R5?, together with the adjacent atom to which they are each attached, form C3-10 carbocyclyl or C3-10 heterocyclyl. Further provided are a method of using the above-described compound, or the pharmaceutically acceptable salt, metabolite, or prodrug thereof for treating influenza and a pharmaceutical composition containing same.

Abstract: A trans-isomeric compound of formula (I) below or a pharmaceutically acceptable salt thereof: in which R1 is C1-C5 alkyl or C3-C5 cycloalkyl and the trans-isomeric compound has a trans:cis ratio of at least 70:30. Further disclosed is a method for preparing the trans-isomeric compound.

Abstract: Provided is a compound of Formula (I) below, or a pharmaceutically acceptable salt, metabolite, or prodrug thereof: wherein: A1 is CR4 or N; A2 is CR5R6 or NR7; A3 is CR5?R6? or NR7?; each of R1, R2, R2?, R3, R3?, R4, R5, R5?, R6, R6?, R7, and R7?, independently, is hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, amino, formyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkylamine, C3-20 carbocyclyl, or C3-20 heterocyclyl; or R5 and R6, R5? and R6?, or R5 and R5?, together with the adjacent atom to which they are each attached, form C3-10 carbocyclyl or C3-10 heterocyclyl. Further provided are a method of using the above-described compound, or the pharmaceutically acceptable salt, metabolite, or prodrug thereof for treating influenza and a pharmaceutical composition containing same.

Abstract: A trans-isomeric compound of formula (I) below or a pharmaceutically acceptable salt thereof: in which R1 is C1-C5 alkyl or C3-C5 cycloalkyl and the trans-isomeric compound has a trans:cis ratio of at least 70:30. Further disclosed is a method for preparing the trans-isomeric compound.

Abstract: A spray-dried solid dispersion containing a pharmaceutical compound of formula (I) shown below and a pharmaceutically acceptable polymer, in which the pharmaceutical compound is dispersed in a polymer matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing such a solid dispersion and using it for treating hepatitis C virus infection and a pharmaceutical formulation containing same.

Abstract: A scanner capable of executing a static calibration and a compensation value adjustment method therefor are disclosed. The scanner includes a calibration piece, a memory, an image capturing unit and a processing unit. The image capturing unit acquires an initial scanned pixel data. A compensation offset-ratio data having a first offset-ratio average is generated according to the initial scanned pixel data and a standard compensation data by the processing unit. Plural selected pixels are determined according to the compensation offset-ratio data, the first offset-ratio average and the predetermined compensation threshold value. A second offset-ratio average is obtained by removing the compensation offset-ratio values of the compensation offset-ratio data of the selected pixels. The initial scanned pixel data is transformed into a static compensation pixel data according to the second offset-ratio average and the standard compensation data.

Abstract: A method of mobilizing cells expressing the type 4 CXC chemokine receptor into the peripheral circulation by contacting them with an effective amount of a compound of formula (I) shown below (each variable in the formula being defined in the Specification): The method can be used to treat cancer and myocardial infarction.

Abstract: A method of mobilizing cells expressing the type 4 CXC chemokine receptor into the peripheral circulation by contacting them with an effective amount of a compound of formula (I) shown below (each variable in the formula being defined in the Specification): The method can be used to treat cancer and myocardial infarction.

Abstract: This invention relates to a method of treating infection by methicillin-nonsusceptibale bacteria, vancomycin-nonsusceptibale bacteria, penicillin-nonsusceptibale bacteria, clarithromycin-nonsusceptibale bacteria, or metronidazole-nonsusceptibale bacteria by administering to a subject in need thereof an effective amount of a compound of the following formula:

Abstract: This invention relates to a malic acid salt of (3S,5R)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid. Also disclosed is a method of treating bacterial infection by an effective amount of this salt.

Abstract: This invention relates to a method of treating pneumonia by orally administering to a subject in need thereof a quinolone compound of formula (I), shown in the disclosure, at a daily dose of 2-30 mg/kg.

Abstract: This invention relates to treating cancer or an angiogenesis-related disease using a compound of formula 1: wherein R1, R2, R3, R4, and n are defined herein.

Abstract: This invention relates to a method of treating infection by methicillin-nonsusceptibale bacteria, vancomycin-nonsusceptibale bacteria, penicillin-nonsusceptibale bacteria, clarithromycin-nonsusceptibale bacteria, or metronidazole-nonsusceptibale bacteria by administering to a subject in need thereof an effective amount of a compound of the following formula:

Abstract: This invention relates to treating an infection with a virus using protease inhibitors. Examples of the protease inhibitors include compounds of formula (II). Each variable is defined in the specification.

Abstract: A single-cluster lamp drive device makes use of a controller to receive video data from a control system and then divides the video data into three sub video data. Next, these three sub video data are simultaneously and repetitively outputted to a digital-to-analog converter in every fixed time interval. Subsequently, the digital-to-analog converter converts these three sub video data to three analog voltages outputted to a voltage-to-current converter. Finally, the voltage-to-current converter converts these three analog voltages to three analog currents for driving light emitting devices to emit light, hence accomplishing voltage-in-current-out driving. The drive device drives a single-cluster lamp composed of one LED or several LEDs to adjust their brightness through current change, thereby coordinating with the control system to produce various color and pattern variations.

Abstract: This invention relates to treating cancer or an angiogenesis-related disease using a compound of formula 1: wherein R1, R2, R3, R4, and n are defined herein.

Abstract: A method of treating cancer including administering to a subject in need thereof an effective amount of a compound of the formula 1: wherein R1, R2, R3, R4, and n are as defined herein.

Abstract: A light emitting device single-cluster lamp control system makes use of a central controller connected with several mutually cascading signal distributors to process already-edited video or multimedia. The central controller then outputs different video data based on the processed video or multimedia, and separately sends the video data via these signal distributors to various light emitting device single-cluster lamp groups to display an image pattern corresponding to the video data. Each light emitting device single-cluster lamp group is installed at a light emitting body (e.g., a building lighting, a landscape lighting, or a billboard) composed of several light emitting device single-cluster lamps.

Abstract: A single-cluster lamp drive device makes use of a controller to receive video data from a control system and then divides the video data into three sub video data. Next, these three sub video data are simultaneously and repetitively outputted to a digital-to-analog converter in every fixed time interval. Subsequently, the digital-to-analog converter converts these three sub video data to three analog voltages outputted to a voltage-to-current converter. Finally, the voltage-to-current converter converts these three analog voltages to three analog currents for driving light emitting devices to emit light, hence accomplishing voltage-in-current-out driving. The drive device drives a single-cluster lamp composed of one LED or several LEDs to adjust their brightness through current change, thereby coordinating with the control system to produce various color and pattern variations.